This study is a multicenter, open-label, prospective, randomized parallel-controlled trial. The purpose is to explore whether the incidence rate of reflux esophagitis (RE) within 12 months after surgery is non-inferior for the DFT group compared to the DTR group.
Age between 20 and 80 years, regardless of gender;
Patients diagnosed with gastric cancer through tissue biopsy;
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
American Society of Anesthesiologists (ASA) classification of I to III;
Received preoperative chemotherapy, radiotherapy, targeted therapy, or immunotherapy;
Presence of contraindications to surgery;
Multiple malignant lesions in the stomach;
Presence of other malignancies that may affect the preservation of stomach function;